RXRX vs ABSI
RXRX 与 ABSI 的估值与基本面并排对比(公开数据)。
关键统计
| 指标 | RXRXRecursion Pharmaceuticals, Inc. | ABSIABSCI CORP |
|---|---|---|
| 市值 | $2.15B | $1.91B |
| 市销率 | 28.9x | 682.2x |
| 营收同比增长 | 26.9% | -38.2% |
| 净利同比增长 | -39.1% | -11.7% |
| 息税前利润率 | -867.9% | -4297.0% |
| 净资产收益率 | -70.5% | -46.8% |
| 投入资本回报率 | -175.2% | -84.6% |
| 一年总回报 | -28.5% | +172.1% |
数据来自 SEC 文件 · 仅供参考 · 非投资建议
1 万美元的成长:RXRX vs ABSI
| 指标 | RXRX | ABSI |
|---|---|---|
| 期末价值 | $1.1K | $5.2K |
| 总回报 | -88.8% | -48.5% |
| 年化收益 (CAGR) | -34.0% | -11.8% |
| 波动率 | 93.2% | 98.2% |
| 夏普比率 | -0.05 | 0.31 |
| 索提诺比率 | -0.08 | 0.48 |
| 最大回撤 | -92.1% | -96.2% |
基于 1326 个共同交易日,2021-07-22 → 2026-10-30 · 无风险利率 4.16%(当前短端国债,全程恒定)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
相关对比
数据延迟 · 公开数据 · 仅供参考 · 非投资建议(本页不评判孰优孰劣)